Kornimate/medical-research-clean huggingface dataset:
comparison of oraquick hcv rapid antibody test and standard serologic screening for hepatitis c: validity, acceptability and impact on linkage to care

Conditions: Active or Ex-injection Drug Users; Indication of Hepatitis C Screening

Summary: rapid tests are increasingly used in medical practice, notably to screen for hiv. their use has been associated with a faster linkage to care and lower rates of loss to follow up. rapid tests are also well accepted by patients and clinicians. no rapid test is currently approved in canada for screening of hepatitis c. hepatitis c diagnosis is done through based on blood testing and the screening algorithm may require up to 3 visits to clarify the hepatitis c status. the oraquick hcv test is a rapid test done on blood or saliva that can replace the first step of the regular screening algorithm. with this test the initial screening and the confirmation test can be done in one visit. the primary endpoint of this pilot-project is to evaluate clinical characteristics of oracquick hcv (sensitivity, specificity, positive and negative predictive values) and to compare them to those of the standard screening algorithm in a population of active or ex-users of injected drugs. the project also intend to evaluate if the rapid test can reduce the rates of loss to follow up and increase the linkage to hepatitis c specialized care. this last endpoint will be evaluated through phone call follow up 6 months after the screening. one hundred and fifty patients will be included. half will be tested with the standard algorithm and the oraquick hcv test (group a) and half will be tested only with the standard algorithm. results of group a will be used to determine the clinical characteristics of oraquick hcv. results of groups a and b will be used to evaluate rates of loss to follow up, costs avoided by the use of the rapid test and linkage to care of infected patients.


Eligibility criteria:
inclusion criteria: * indication of hepatitis c screening * active or ex-injection drug user exclusion criteria: * known hepatitis c infection * unknown hiv status and patient refusing to hiv testing
role of endorphins in the perception of dyspnea in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: endorphins are naturally occurring narcotic substances that are released when individuals perform exercise. the hypothesis of the study is that endorphins reduce the severity of breathlessness during exercise in patients with chronic obstructive pulmonary disease (copd). the initial five visits include familiarization and validation of a computerized system for patients to report dyspnea and leg discomfort continuously during exercise testing. at visits 6 and 7 blood is drawn to measure serum endorphin levels pre-exercise, end exercise, and 30 minutes after exercise. normal saline or naloxone is given intravenously 5 minutes prior to exercise in a double-blinded design. the primary outcome is the slope of oxygen consumption - dyspnea.


Eligibility criteria:
inclusion criteria: * diagnosis of copd * ability to exercise * ability to computer mouse to provide ratings * \> 10 pack-years smoking * baseline dyspnea index \< 9 exclusion criteria: * clinically significant comorbidities

Keywords: dyspnea; leg discomfort; exercise duration
comparison of a single dose combination of methadone and morphine with morphine alone for treating post-operative pain

Conditions: Pain

Summary: this is a randomized phase ii study testing the effectiveness of the combination of morphine and methadone versus morphine alone in relieving pain. a second goal is to further evaluate any side effects of the combination of morphine and methadone.

rationale: experimental data demonstrates a profound analgesic synergy between morphine and methadone when co-administered systemically in mice. if this type of synergy can be demonstrated in clinical pain, it will be a relatively unique example of translating concepts of fundamental aspects of opioid actions seen in the laboratory to the clinical area, and provide a basis for offering new and scientifically- based analgesic regimens. this may provide better pain relief with less opioid related side effects in clinical practice. purpose: this is a randomized, double blind, parallel arm phase ii study comparing a single dose of 1:1 combination of methadone and morphine with morphine alone in patients with post-operative pain. * the primary objective of this randomized, double blind, parallel arm phase ii study is to compare the analgesic effects of a combination of morphine and methadone with morphine alone to determine synergistic activity of mu opioid analgesics in patients with post-operative pain. * a second goal is to further evaluate any side effects of the combination of morphine and methadone.

Eligibility criteria:
inclusion criteria: * retroperitoneal lymph node dissection * planned post-operative analgesia with pca at 1 mg continuous infusion and 1 mg every 10 minutes * 18 years of age or older * english-speaking * give informed consent to participate in this study exclusion criteria: * known hypersensitivity to methadone or morphine * patients with past or present history of substance abuse * patients with a history of methadone treatment * patients with a history of chronic pain requiring daily analgesic use for more than 3 months * patients treated with opioids within one month from the scheduled surgery * creatinine clearance less than 50 mg/kg (using cockcroft-gault equation). * neurologic or psychiatric disease sufficient, in the doctor's opinion, to compromise data collection

Keywords: pain analgesics retroperitoneal lymph node dissection
comparison of doxycycline and cefuroxime axetil in erythema migrans

Conditions: Erythema Chronicum Migrans

Summary: a european, prospective clinical trial in which doxycycline and cefuroxime axetil were compared in the treatment of adult patients with erythema migrans included a control group to address this question. evaluations of patients were conducted at baseline, 14 days and 2, 6, and 12 months after enrollment. control subjects were evaluated at baseline and at 6 and 12 months. subjective complaints that newly developed or intensified since the onset of erythema migrans or since the date of enrollment for controls were referred to as "new or increased symptoms"(nois).


Eligibility criteria:
inclusion criteria: * typical solitary erythema migrans as defined by the united states centers for disease control and prevention. in addition, patients with skin lesion \<5 cm in diameter were also included if they recalled a recent tick bite at the site of the skin lesion, had a symptom-free interval between the bite and the onset of the lesion, and reported an expanding skin lesion prior to diagnosis. exclusion criteria: * lyme disease previously * pregnancy or lactation * immunocompromised * serious adverse reaction to a beta-lactam or tetracycline drug in the past * received an antibiotic with known anti-borrelial activity within 10 days * multiple erythema migrans lesions * presence of an extracutaneous manifestation of lyme disease
reliabılıty,validity of the turkish version of the nih-minimal dataset

Conditions: Low Back Pain

Summary: this study, we performed the turkish version validity and reliability of the nih task force's recommended multidimensional minimal dataset

low back pain is defined as the pain that can occur in the region between the lower border of the scapula and the hip, sometimes spreading to the lower extremities, which causes activity limitation and is one of the most common health problems in the society. appropriate use of assessment questionnaires is one of the most important steps in the evaluation of the functional level of the patient and in deciding on an effective treatment protocol. the purpose of our study is to determine the turkish version, validity and reliability of nih task force's recommended multidimensional minimal dataset. 200 patients with chronic low back pain were included in the study. test-retest and internal consistency analysis were conducted to determine the reliability of the questionnaire.

Eligibility criteria:
inclusion criteria: * having a low back pain literate exclusion criteria: * pregnant, * canser * trauma

Keywords: validity reliability low back apain translation
improved self management in uncontrolled systolic hypertension

Conditions: Systolic Hypertension

Summary: patients who receive smartphone-assisted health coaching will have a significantly lower 24 hour ambulatory blood pressure mean than patients who receive just health coaching

primary outcome measure: mean 24 hour ambulatory blood pressure secondary outcome measures: profile of mood states-sf vigor scale; satisfaction with life scale; positive and negative affect schedule; hospital anxiety and depression scale; sf - 12

Eligibility criteria:
inclusion criteria: * 25 - 70 years old; * mean daytime systolic bp\> 130 mm. hg. exclusion criteria: * severe or end-stage organ disease (liver, kidney, heart, lung) or history of diabetic ketoacidosis, or any other illness with expected survival less than 1 year; * severe cognitive impairment; * diagnosed psychiatric illness or disability; * clinical significant cardiac arrhythmia; * symptomatic orthostatic hypertension; * pregnancy; * not fluent in english.

Keywords: hypertension, systolic, uncontrolled
study of ati-450 vs placebo in patients with moderate to severe psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: this is a phase 2a study to investigate the efficacy, safety, tolerability, pk, and pd of ati-450 versus placebo in patients with moderate to severe psoriatic arthritis.

this is a phase 2a, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, pk, and pd of ati-450 versus placebo in patients with moderate to severe psoriatic arthritis.

Eligibility criteria:
inclusion criteria: * diagnosis of psa with symptom onset at least 6 months before the screening visit and fulfilment of the classification criteria for psa. * patient has moderate-to-severe psa at screening and randomization visits defined as * ≥3 tender joints (based on 68 joint counts) and * ≥3 swollen joints (based on 66 joint counts). * diagnosis of active plaque psoriasis or documented history of plaque psoriasis. exclusion criteria: * any arthritis with onset before age 17 years, or current diagnosis of inflammatory joint disease other than psa, or other immunological disease (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus). * patient has an uncontrolled non-immunoinflammatory disease that may place the patient at increased risk during the study or impact the interpretation of results, eg, cirrhosis, previous malignancy, previous venous thromboembolism. * any clinically significant laboratory abnormality that would affect interpretation of study data or safety of the patient's participation in the study, per judgment of the investigator.

Keywords: arthritis psoriatic
randomized microport's firehawk des versus xience v: target i trial

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to evaluate new generation drug eluting stent (des) of microport of its safety, efficacy and delivery system in treating cad.

the primary endpoint is in-stent late lumen loss after 9 months of the stent implantation. the secondary endpoint is in-stent percent diameter stenosis.this study is based on non-inferior assumption (vs. xience v), requiring both endpoints reach statistical significance. prespecified oct follow-up is planned at 3-year after index procedure at 3 chosen hospitals.

Eligibility criteria:
inclusion criteria: * age 18-75, male or women who are not pregnant * evidence of non-symptomatic ischemia, stable or non-stable angina or past heart attack cases * target lesion is primary, single artery and single lesion of coronary artery * target lesion vessel length ≤24mm, diameter 2.25mm-4.0mm * lesion diameter stenosis ≥70% * candidates understand the study, willing to sign consent of agreement and to willing to accept follow-up for long lesion group, at least one target lesion length ≥28mm，diameter 2.5mm-4.0mm, and one lesion needs to implant 33mm 0r 38mm long stent exclusion criteria: * acute heart attack within one week * chronic complete stenosis (timi 0), left main lesion, three branches need to treat, branch vessel diameter ≤2.5mm and bypass lesion * calcified lesion failed in pre-dilation and twisted lesion * in-stent restenosis * stent implanted within one year * severe heart failure (nyha above iii) or left ventricle ef \<40% * renal function damage, blood creatinine \>2.0mg/dl * bleeding risk; allergic to drugs and agents used in procedure/treatment * life expectation \< 12 months * no compliances to the protocol * heart implantation cases pre-specified oct inclusion/exclusion criteria: * patients underwent 9-month angio f/u * no binary restenosis at 9-month * lll between -0.01\~0.2mm * no mix-implanted stent * no more than one bail-out stent * no tlr occurred at 3 years after pci * the target vessel able to deliver the oct catheter
renal denervation to improve outcomes in patients with end-stage renal disease

Conditions: End-stage Renal Disease; Hypertension

Summary: sympathetic activation is a hallmark of end-stage renal disease and adversely affects cardiovascular prognosis. hypertension is present in the vast majority of these patients and plays a key role in the progressive deterioration of renal function and in the exceedingly high rate of cardiovascular events. selective catheter-based renal denervation has been shown to be safe and effective in attaining improved and sustained blood pressure control in patients with resistant hypertension and normal renal function. the investigators hypothesize that catheter-based renal denervation is a safe and effective intervention to achieve sustained reduction in sympathetic nerve activity, bp and target organ damage in hypertensive end-stage renal disease (esrd) patients, which will result in improved cardiovascular outcomes.


Eligibility criteria:
inclusion criteria: * end stage renal disease * hypertension (bp≥140/90mmhg) exclusion criteria: * individual has renal artery anatomy that is ineligible for treatment as assessed by the interventionalist. * individual has experienced a myocardial infarction, unstable angina, or a cerebrovascular accident within 3 months of the screening visit.
online adaptive radiotherapy using a novel linear accelerator (ethos)

Conditions: Prostate Cancer; Head and Neck Cancer; NSCLC; SCLC; Esophageal Cancer; Bladder Cancer; Rectum Cancer; Cervix Cancer; Other Carcinoma

Summary: the study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (art) using the varian/shs ethos treatment system. in this study, radiation treatment plans are dynamically adjusted on a daily basis over several weeks of therapy to account for anatomical shifts in either the tumour or adjacent normal tissue - a capability that has been difficult to achieve due to technical limitations. with the ethos accelerator, such real-time adjustments can be made based on cone beam computed tomography (cbct). this is a prospective observational study with the primary objective of investigating the feasibility and acceptability of performing art with ethos for different tumour entities. the study will also evaluate the feasibility of integrating multi-parametric data sets into the art workflow, such as standardised electronic feedback on treatment toxicity from both patients (eproms) and physicians (eprt).


Eligibility criteria:
inclusion criteria: * adult patients (\>18 years) * all tumor entities with an indication for radiotherapy and/or chemoradiotherapy * signed informed consent exclusion criteria: * pregnancy * patients who are not capable of giving consent

Keywords: online adaptive radiation therapy art cone beam ct eproms
'my life is music' group therapy model - a feasibility study for adolescents with persistent pain

Conditions: Pediatric Pain

Summary: the aim of this multi-method feasibility study is to learn if a group therapy model using music can be applied in the treatment of adolescents with persistent pain. we are interested how the patients find participating in the group therapy as part of their rehabilitation and if the patient´s experience of music changes during the therapy process.


Eligibility criteria:
inclusion criteria: * persistent pain (3 months) * fluency in finnish language exclusion criteria: - a psychiatric illness that significantly impairs functioning

Keywords: pediatric pain music therapy group therapy music intervention persistent pain
evaluating edema and range of motion using negative pressure therapy vs. standard surgical dressing in bilateral tka

Conditions: Surgical Wound; Bilateral Total Knee Arthroplasty; Wounds and Injuries; Joint Diseases; Musculoskeletal Diseases; Edema Leg; Joint Pain; Arthritis Knee

Summary: this study will compare the effects of closed incision negative pressure dressing vs. standard of care silver dressing on lower limb swelling after bilateral primary total knee arthroplasty.


Eligibility criteria:
inclusion criteria: * is at least 22 years of age on the date of informed consent. * can independently provide informed consent. * requires and is scheduled to undergo a simultaneous, bilateral, primary tka. * is willing and physically capable of undergoing a simultaneous, bilateral, primary tka with or without replacement of the patella. * is willing and able to return for all scheduled study visits. exclusion criteria: * is pregnant or lactating. * has signs of an infection in the area of either knee or has signs of a systemic infection at the time of surgery. * is a chronic opioid user, defined per the cdc guidelines as opioid use for \>3 months, at the time of enrollment. * has a current diagnosis of lymphedema in either leg. * has signs, symptoms, or a current diagnosis of venous insufficiency in either leg, as determined by the investigator's review of the subject's medical history. * has a history of clotting disorder or prior history of deep vein thrombosis * will undergo a unilateral tka. * will undergo a staged, bilateral tka. * has had previous knee replacement surgery. * has received a corticosteroid injection into either knee within 30 days of surgery. * undergoes a simultaneous, bilateral tka with a planned different incision type on each knee (eg, midline incision vs. medial parapatellar incision). * has known sensitivity to the study product components (drape and/or dressing materials in direct contact with the closed incision or skin). * has known sensitivity to silver. * is enrolled in another interventional clinical study. * has skin cancer localized at or in proximity to the incision site. * does not have access to an electronic device (smartphone, ipad, or computer) on a daily basis to complete online assessments. * has condition(s) that, in the opinion of the investigator, cause the subject to be an overall health risk that is unsuitable for the surgery. * has condition(s) that, in the opinion of the investigator, will impact study endpoints (eg, hemophilia or autoimmune disorders) or the ability to comply with study procedures. intra-op exclusion criteria: * does not receive a "total" knee replacement for first knee. for example, a partial or uni-compartmental knee replacement is performed * has a surgical incision that would preclude placement of either dressing onto the knee * has a tka resulting in a muscle flap
to demonstrate the relative bioavailability of cyclobenzaprine hcl tablets

Conditions: Depression

Summary: to demonstrate the relative bioavailability of cyclobenzaprine hcl tablets.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.

Keywords: antidepressant
study of genic expression profiles of the epithelium of the nose and bronchi in healthy and allergic subjects

Conditions: Allergy

Summary: the respiratory epithelium plays a leading role in the development of allergic respiratory disease with barrier function alteration, its repair mechanisms, of anti-viral fight and the ability to induce by itself th2 responses. the majority of allergic asthmatic patients have reached concomitant ent: the concept of "one airway, one disease." access to this material of epithelial study in the different phenotypes of the disease appears to be crucial. nasal and bronchial epithelial tissues reveal essential differences in particular related to their environment (remodeling less intense and a lower sensitivity to the virus in the nose), but they nevertheless share many common cellular characteristics.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years and \<30 years * isolated allergic rhinitis according to clinical criteria aria * absence of asthma whose diagnosis is made based on clinical criteria or mild to moderate persistent asthma controlled with a diagnosis is made based on clinical criteria exclusion criteria: * recent rhino-bronchial infection (\<6 weeks) * asthma exacerbation in the previous 6 weeks * chronic disease may in the opinion of the investigators interfere with the results of the study or expose them to additional risk. * treatment with nasal corticosteroids, inhaled or systemic in the past 6 weeks * current smoking no history of smoking or not smoking for at least 12 months and weaned smoking history \<5 pack-years) * special needs
biomarkers in patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is studying biomarkers in patients with acute myeloid leukemia.

objectives: * to determine whether clonally expanded somatic mitochondrial dna mutations are associated with acute myeloid leukemia. outline: genomic dna from blood samples obtained at diagnosis, remission, and relapse are analyzed for mitochondrial dna mutations via pcr.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia * available blood samples from diagnosis, remission, and relapse patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adult acute myeloid leukemia childhood acute myeloid leukemia/other myeloid malignancies